Molecular structure of SB220025, CAS Number: 165806-53-1
SB220025 (CAS 165806-53-1)
Alternate Names:
5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinyl)imidazole
Application:
SB220025 is a specific and potent human p38 mitogen-activated protein kinase
CAS Number:
165806-53-1
Purity:
≥95%
Molecular Weight:
338.4
Molecular Formula:
C18H19FN6
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
SB220025 is a compound that functions as a potent and selective inhibitor of the p38 mitogen-activated protein kinase (MAPK) pathway. It exerts its mechanism of action by targeting and binding to the ATP-binding site of p38 MAPK, thereby preventing its activation and subsequent phosphorylation of downstream substrates. This inhibition ultimately leads to the suppression of pro-inflammatory cytokine production and gene expression. By interfering with the p38 MAPK signaling cascade, SB220025 plays a role in modulating cellular responses to various stress stimuli, including inflammatory and immune responses.
SB220025 (CAS 165806-53-1) References
- Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner. | Casanovas, O., et al. 2000. J Biol Chem. 275: 35091-7. PMID: 10952989
- A simple technique for high-throughput screening of drugs that modulate normal and psoriasis-like differentiation in cultured human keratinocytes. | Pol, A., et al. 2002. Skin Pharmacol Appl Skin Physiol. 15: 252-61. PMID: 12218287
- A role for COX-2 and p38 mitogen activated protein kinase in long-term depression in the rat dentate gyrus in vitro. | Murray, HJ. and O'Connor, JJ. 2003. Neuropharmacology. 44: 374-80. PMID: 12604095
- Inhibitor of p42/44 mitogen-activated protein kinase, but not p38 MAPK, attenuated antigen challenge of guinea pig airways in vitro. | Chue, SC., et al. 2004. Int Immunopharmacol. 4: 1089-98. PMID: 15222984
- Inhibition of RIP2/RIck/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK. | Argast, GM., et al. 2005. Mol Cell Biochem. 268: 129-40. PMID: 15724446
- p38 mitogen-activated protein kinase (MAPK) first regulates filamentous actin at the 8-16-cell stage during preimplantation development. | Paliga, AJ., et al. 2005. Biol Cell. 97: 629-40. PMID: 15850458
- Activation of p38MAPK signaling cascade in a VSMC injury model: role of p38MAPK inhibitors in limiting VSMC proliferation. | Jacob, T., et al. 2005. Eur J Vasc Endovasc Surg. 29: 470-8. PMID: 15966085
- Mitogen-activated protein kinase (MAPK) blockade of bovine preimplantation embryogenesis requires inhibition of both p38 and extracellular signal-regulated kinase (ERK) pathways. | Madan, P., et al. 2005. Reproduction. 130: 41-51. PMID: 15985630
- Inhibition of p38 mitogen-activated protein kinase enhances c-Jun N-terminal kinase activity: implication in inducible nitric oxide synthase expression. | Lahti, A., et al. 2006. BMC Pharmacol. 6: 5. PMID: 16504051
- PP2Cdelta (Ppm1d, WIP1), an endogenous inhibitor of p38 MAPK, is regulated along with Trp53 and Cdkn2a following p38 MAPK inhibition during mouse preimplantation development. | Hickson, JA., et al. 2007. Mol Reprod Dev. 74: 821-34. PMID: 17219434
- The inhibitory effect of docetaxel and p38 MAPK inhibitor on TZT-1027 (Soblidotin)-induced antivascular activity. | Watanabe, J., et al. 2007. Anticancer Res. 27: 3909-18. PMID: 18225550
- Apolipoprotein E induces antiinflammatory phenotype in macrophages. | Baitsch, D., et al. 2011. Arterioscler Thromb Vasc Biol. 31: 1160-8. PMID: 21350196
- The p38 mitogen-activated protein kinases modulate endothelial cell survival and tissue repair. | Kanaji, N., et al. 2012. Inflamm Res. 61: 233-44. PMID: 22138711
- Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. | Jackson, JR., et al. 1998. J Pharmacol Exp Ther. 284: 687-92. PMID: 9454815
- Structural basis of inhibitor selectivity in MAP kinases. | Wang, Z., et al. 1998. Structure. 6: 1117-28. PMID: 9753691
Inhibitor of:
p38, and Ser/Thr Protein Kinase.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SB220025, 500 µg | sc-202804 | 500 µg | $359.00 |